American Financial Group Inc. held its stake in shares of Axovant Sciences Ltd. (NYSE:AXON) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 172,395 shares of the company’s stock at the end of the third quarter. American Financial Group Inc. owned approximately 0.17% of Axovant Sciences worth $2,414,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Ghost Tree Capital LLC bought a new stake in Axovant Sciences during the second quarter worth approximately $7,383,000. Citadel Advisors LLC raised its stake in shares of Axovant Sciences by 850.3% in the second quarter. Citadel Advisors LLC now owns 572,679 shares of the company’s stock valued at $7,353,000 after buying an additional 512,413 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Axovant Sciences by 69.2% in the second quarter. BlackRock Fund Advisors now owns 574,250 shares of the company’s stock valued at $7,373,000 after buying an additional 234,904 shares during the last quarter. Sabby Management LLC raised its stake in shares of Axovant Sciences by 458.2% in the second quarter. Sabby Management LLC now owns 190,000 shares of the company’s stock valued at $2,440,000 after buying an additional 155,960 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in shares of Axovant Sciences by 86.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 222,255 shares of the company’s stock valued at $2,854,000 after buying an additional 103,135 shares during the last quarter.

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Shares of Axovant Sciences Ltd. (NYSE:AXON) traded down 2.21% during mid-day trading on Tuesday, hitting $13.70. The stock had a trading volume of 231,488 shares. The stock’s 50-day moving average price is $13.10 and its 200-day moving average price is $13.86. Axovant Sciences Ltd. has a 52-week low of $8.86 and a 52-week high of $21.30. The firm’s market cap is $1.36 billion.

WARNING: “American Financial Group Inc. Has $2,414,000 Position in Axovant Sciences Ltd. (AXON)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and reposted in violation of US and international copyright & trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/29/american-financial-group-inc-has-2414000-position-in-axovant-sciences-ltd-axon.html.

Several equities research analysts recently commented on the company. HC Wainwright restated a “buy” rating on shares of Axovant Sciences in a research report on Wednesday, August 17th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research report on Monday, August 8th. Evercore ISI restated a “buy” rating and set a $29.00 target price on shares of Axovant Sciences in a research report on Friday, September 23rd. Jefferies Group restated a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a research report on Monday, September 26th. Finally, JMP Securities restated a “buy” rating on shares of Axovant Sciences in a research report on Tuesday, November 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.33.

About Axovant Sciences

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

5 Day Chart for NYSE:AXON

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.